cohbar
host
key
opinion
leader
meeting
antifibrotic
peptides
potential
treatment
idiopathic
pulmonary
fibrosis
menlo
park
globe
newswire
cohbar
nasdaq
cwbr
clinical
stage
biotechnology
company
developing
mitochondria
based
therapeutics
treat
chronic
diseases
extend
healthy
lifespan
today
announced
host
key
opinion
leader
kol
webinar
current
treatment
landscape
idiopathic
pulmonary
fibrosis
ipf
unmet
medical
need
positive
findings
preclinical
studies
analogs
friday
november
et
call
feature
presentation
kol
toby
maher
md
director
interstitial
lung
disease
professor
medicine
keck
school
medicine
university
southern
california
discuss
current
treatment
landscape
unmet
medical
need
treating
patients
ipf
maher
available
answer
questions
following
formal
presentations
cohbar
management
team
provide
overview
antifibrotic
peptides
analogs
also
give
update
recently
announced
positive
data
demonstrating
combination
analog
nintedanib
leading
standard
care
treatment
ipf
produced
enhanced
effects
therapeutic
mouse
model
ipf
compared
nintedanib
alone
specifically
combination
produced
greater
reductions
fibrosis
inflammation
cytokine
levels
collagen
deposition
versus
nintedanib
monotherapy
register
webinar
please
click
toby
maher
professor
clinical
medicine
keck
school
medicine
university
southern
california
additionally
maher
british
lung
foundation
chair
respiratory
research
national
institute
health
research
nihr
clinician
scientist
professor
interstitial
lung
disease
heads
fibrosis
research
group
national
heart
lung
institute
imperial
college
london
also
honorary
consultant
respiratory
physician
interstitial
lung
disease
unit
royal
brompton
hospital
director
nihr
respiratory
crf
director
respiratory
research
royal
brompton
hospital
research
interests
include
biomarker
discovery
lung
microbiome
host
immune
response
pathogenesis
ipf
clinical
trials
interstitial
lung
disease
involved
trials
fibrotic
lung
disease
phase
phase
including
assessing
ipf
scleroderma
rheumatoid
arthritis
inflammatory
myositis
overall
recruited
patients
interventional
studies
given
expert
opinions
food
drug
administration
european
medicines
agency
associate
editor
american
journal
respiratory
critical
care
medicine
international
advisory
board
lancet
respiratory
medicine
authored
papers
book
chapters
pulmonary
fibrosis
cohbar
cohbar
nasdaq
cwbr
clinical
stage
biotechnology
company
focused
research
development
mitochondria
based
therapeutics
emerging
class
drugs
treatment
chronic
diseases
mitochondria
based
therapeutics
originate
discovery
cohbar
founders
novel
group
naturally
occurring
peptide
sequences
within
mitochondrial
genome
shown
potential
regulate
key
processes
multiple
systems
organs
body
date
company
discovered
mitochondrial
derived
peptides
generated
analogs
cohbar
efforts
focus
development
peptides
therapeutics
offer
potential
address
broad
range
diseases
underlying
impact
mitochondrial
dysfunction
company
lead
compound
phase
stage
phase
clinical
trial
nash
obesity
addition
cohbar
four
preclinical
programs
analogs
fibrotic
diseases
analogs
associated
ards
analogs
cancer
orphan
diseases
analogs
cancer
immunotherapy
additional
company
information
please
visit
statements
news
release
contains
statements
historical
facts
within
meaning
private
securities
litigation
reform
act
statements
based
current
beliefs
expectations
assumptions
regarding
future
business
future
plans
strategies
projections
anticipated
events
future
conditions
cases
identify
statements
words
believe
may
estimate
continue
anticipate
intend
could
would
project
plan
expect
goal
seek
future
likely
negative
plural
words
similar
expressions
examples
statements
include
limited
statements
regarding
anticipated
outcomes
research
clinical
trials
mitochondria
based
therapeutic
mbt
candidates
expectations
regarding
growth
mbts
significant
future
class
drug
products
statements
regarding
anticipated
therapeutic
properties
potential
mitochondrial
peptide
analogs
mbts
potential
therapies
including
limited
treatment
ipf
cautioned
statements
guarantees
future
performance
actual
results
developments
may
differ
materially
set
forth
statements
factors
could
cause
actual
results
differ
materially
statements
include
ability
successfully
advance
drug
discovery
development
programs
including
delay
termination
ongoing
clinical
trials
possible
inability
mitigate
prevalence
persistence
injection
site
reactions
receipt
unfavorable
feedback
regulators
regarding
safety
tolerability
possibility
developments
affecting
viability
clinical
candidate
commercial
potential
results
different
earlier
data
results
including
less
favorable
may
support
clinical
development
ability
raise
additional
capital
necessary
continue
operations
ability
recruit
retain
key
management
scientific
personnel
risk
intellectual
property
may
adequately
protected
ability
establish
maintain
partnerships
corporate
industry
partners
risks
related
impact
business
pandemic
similar
public
health
crises
additional
assumptions
risks
uncertainties
described
detail
registration
statements
reports
filings
securities
exchange
commission
applicable
canadian
securities
regulators
available
website
cautioned
statements
guarantees
future
performance
actual
results
may
differ
materially
set
forth
statements
statements
information
contained
news
release
made
date
hereof
cohbar
undertake
obligation
update
publicly
revise
statements
information
whether
result
new
information
future
events
otherwise
unless
required
applicable
securities
laws
nothing
herein
shall
constitute
offer
sell
solicitation
offer
buy
securities
contacts
jordyn
tarazi
director
investor
relations
cohbar
joyce
allaire
lifesci
advisors
llc
jallaire
